Puretech Health plc (PRTC) Ordinary 1p

Sell:138.00pBuy:139.00p0.80p (0.57%)

FTSE All Share:0.32%
Market closed | Prices delayed by at least 15 minutes
Sell:138.00p
Buy:139.00p
Change:0.80p (0.57%)
Market closed | Prices delayed by at least 15 minutes
Sell:138.00p
Buy:139.00p
Change:0.80p (0.57%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

Key people

Eric Elenko
President, Director
Bharatt M. Chowrira
Chief Executive Officer, Director
Robert S. Langer
Co-Founder, Non-Executive Director
Charles H. Sherwood
General Counsel, Company Secretary
Robert Lyne
Chief Portfolio Officer
Raju S. Kucherlapati
Lead Independent Non-Executive Chairman of the Board
Robert J. Hombach
Director
Sharon Barber-lui
Non-Executive Independent Director
Michele A. M. Holcomb
Non-Executive Independent Director
John L. Lamattina
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    PRTC
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB00BY2Z0H74
  • Market cap
    £333.86m
  • Employees
    56
  • Shares in issue
    258.70m
  • Exchange
    London Stock Exchange (LON)
  • Index
    FTSE All Share Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.